FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106650746> ?p ?o ?g. }

• W2106650746 endingPage "2966" @default.
• W2106650746 startingPage "2960" @default.
• W2106650746 abstract "Context: GH excess affects approximately 20% of the patients with McCune-Albright syndrome (MAS). MAS is caused by sporadic, postzygotic, activating mutations in the GNAS gene, which codes for the cAMP-regulating protein, Gsα (gsp oncogene). These same mutations are found in approximately one third of the sporadic cases of acromegaly. Objective: We examined efficacy of the GH receptor antagonist, pegvisomant, in controlling gsp oncogene-mediated GH excess and skeletal disease (fibrous dysplasia of bone) associated with MAS. Setting and Patients: Five MAS patients with GH excess were treated with 20 mg/d sc injection of pegvisomant for 12 wk in a randomized, double-blind, placebo-controlled crossover study at the National Institutes of Health. Main Outcome Measures: The primary measure of efficacy was normalization of IGF-I. Secondary outcome measures were reduction in serum IGF binding protein-3 (IGFBP-3), improvement of fatigue and sweating, and reduction in markers of bone metabolism and bone pain. Results: Combined mean changes in serum IGF-I at 6 and 12 wk were −236.4 ng/ml (53%, P < 0.005) and −329.8 ng/ml (62%, P < 0.001), respectively. IGFBP-3 decreased by 0.8 mg/liter (24%, P < 0.01) and 2.9 mg/liter (37%, P < 0.005), respectively. There were no significant changes in signs and symptoms of acromegaly or markers of bone metabolism and bone pain, nor was there a significant change in pituitary size. Retrospective comparison of the degree of control achieved with pegvisomant vs. other medications (long-acting octreotide ± dopamine agonist) in the same group showed that the two regimens were similarly effective. Conclusions: Pegvisomant effectively reduced IGF-I and IGFBP-3 levels in gsp-mediated GH excess but had no effect on fibrous dysplasia." @default.
• W2106650746 created "2016-06-24" @default.
• W2106650746 creator A5000154017 @default.
• W2106650746 creator A5004825233 @default.
• W2106650746 creator A5004844669 @default.
• W2106650746 creator A5026908064 @default.
• W2106650746 creator A5041055257 @default.
• W2106650746 creator A5052945822 @default.
• W2106650746 creator A5072500664 @default.
• W2106650746 creator A5084587886 @default.
• W2106650746 date "2006-08-01" @default.
• W2106650746 modified "2023-09-27" @default.
• W2106650746 title "Pegvisomant for the Treatment of gsp-Mediated Growth Hormone Excess in Patients with McCune-Albright Syndrome" @default.
• W2106650746 cites W1967092942 @default.
• W2106650746 cites W1976263533 @default.
• W2106650746 cites W1983768530 @default.
• W2106650746 cites W1997709006 @default.
• W2106650746 cites W2001038217 @default.
• W2106650746 cites W2022695623 @default.
• W2106650746 cites W2048741547 @default.
• W2106650746 cites W2055486607 @default.
• W2106650746 cites W2059497277 @default.
• W2106650746 cites W2096842658 @default.
• W2106650746 cites W2101632387 @default.
• W2106650746 cites W2103780972 @default.
• W2106650746 cites W2107724413 @default.
• W2106650746 cites W2153200944 @default.
• W2106650746 cites W2154556401 @default.
• W2106650746 cites W2313368498 @default.
• W2106650746 cites W2337777109 @default.
• W2106650746 cites W59831665 @default.
• W2106650746 doi "https://doi.org/10.1210/jc.2005-2661" @default.
• W2106650746 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16720661" @default.
• W2106650746 hasPublicationYear "2006" @default.
• W2106650746 type Work @default.
• W2106650746 sameAs 2106650746 @default.
• W2106650746 citedByCount "45" @default.
• W2106650746 countsByYear W21066507462012 @default.
• W2106650746 countsByYear W21066507462013 @default.
• W2106650746 countsByYear W21066507462014 @default.
• W2106650746 countsByYear W21066507462016 @default.
• W2106650746 countsByYear W21066507462017 @default.
• W2106650746 countsByYear W21066507462018 @default.
• W2106650746 countsByYear W21066507462019 @default.
• W2106650746 countsByYear W21066507462020 @default.
• W2106650746 countsByYear W21066507462021 @default.
• W2106650746 countsByYear W21066507462022 @default.
• W2106650746 countsByYear W21066507462023 @default.
• W2106650746 crossrefType "journal-article" @default.
• W2106650746 hasAuthorship W2106650746A5000154017 @default.
• W2106650746 hasAuthorship W2106650746A5004825233 @default.
• W2106650746 hasAuthorship W2106650746A5004844669 @default.
• W2106650746 hasAuthorship W2106650746A5026908064 @default.
• W2106650746 hasAuthorship W2106650746A5041055257 @default.
• W2106650746 hasAuthorship W2106650746A5052945822 @default.
• W2106650746 hasAuthorship W2106650746A5072500664 @default.
• W2106650746 hasAuthorship W2106650746A5084587886 @default.
• W2106650746 hasBestOaLocation W21066507461 @default.
• W2106650746 hasConcept C104317684 @default.
• W2106650746 hasConcept C126322002 @default.
• W2106650746 hasConcept C134018914 @default.
• W2106650746 hasConcept C142724271 @default.
• W2106650746 hasConcept C151730666 @default.
• W2106650746 hasConcept C204787440 @default.
• W2106650746 hasConcept C27081682 @default.
• W2106650746 hasConcept C2777433750 @default.
• W2106650746 hasConcept C2778886798 @default.
• W2106650746 hasConcept C2779343474 @default.
• W2106650746 hasConcept C2984496839 @default.
• W2106650746 hasConcept C55493867 @default.
• W2106650746 hasConcept C71315377 @default.
• W2106650746 hasConcept C71924100 @default.
• W2106650746 hasConcept C74231797 @default.
• W2106650746 hasConcept C86803240 @default.
• W2106650746 hasConcept C87813604 @default.
• W2106650746 hasConceptScore W2106650746C104317684 @default.
• W2106650746 hasConceptScore W2106650746C126322002 @default.
• W2106650746 hasConceptScore W2106650746C134018914 @default.
• W2106650746 hasConceptScore W2106650746C142724271 @default.
• W2106650746 hasConceptScore W2106650746C151730666 @default.
• W2106650746 hasConceptScore W2106650746C204787440 @default.
• W2106650746 hasConceptScore W2106650746C27081682 @default.
• W2106650746 hasConceptScore W2106650746C2777433750 @default.
• W2106650746 hasConceptScore W2106650746C2778886798 @default.
• W2106650746 hasConceptScore W2106650746C2779343474 @default.
• W2106650746 hasConceptScore W2106650746C2984496839 @default.
• W2106650746 hasConceptScore W2106650746C55493867 @default.
• W2106650746 hasConceptScore W2106650746C71315377 @default.
• W2106650746 hasConceptScore W2106650746C71924100 @default.
• W2106650746 hasConceptScore W2106650746C74231797 @default.
• W2106650746 hasConceptScore W2106650746C86803240 @default.
• W2106650746 hasConceptScore W2106650746C87813604 @default.
• W2106650746 hasIssue "8" @default.
• W2106650746 hasLocation W21066507461 @default.
• W2106650746 hasLocation W21066507462 @default.
• W2106650746 hasLocation W21066507463 @default.
• W2106650746 hasOpenAccess W2106650746 @default.
• W2106650746 hasPrimaryLocation W21066507461 @default.

• next